{
  "symbol": "COR",
  "year": 2024,
  "competition_summary": [
    {
      "competitor": "Walgreens Boots Alliance, Inc.",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    },
    {
      "competitor": "Alliance Healthcare",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    },
    {
      "competitor": "PharmaLex",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    },
    {
      "competitor": "OneOncology",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    },
    {
      "competitor": "Retina Consultants of America",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    },
    {
      "competitor": "the U.S. Foreign Corrupt Practices Act",
      "mentions": 1,
      "context": "competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; \u2022 risks associated with our strategic, long-term relationship with Walgreens Boots Alliance, Inc. (\"WBA\"), including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; \u2022 risks that acquisitions of or investments in businesses, including the acquisitions of Alliance Healthcare and P"
    }
  ]
}